<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150644</url>
  </required_header>
  <id_info>
    <org_study_id>C02-003</org_study_id>
    <nct_id>NCT00150644</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Asoprisnil(J867) in Women With Uterine Fibroids Who Are Scheduled for a Hysterectomy</brief_title>
  <official_title>A Phase 2, 12-Week, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of J867 on Uterine Artery Blood Flow and the Morphology of the Endometrium, Myometrium, and Uterine Leiomyomata in Subjects With Uterine Leiomyomata Scheduled for Hysterectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effects of 10 mg and 25 mg doses of
      asoprisnil, compared to placebo, taken daily for 12 weeks, on uterine blood flow and the
      morphology of the endometrium and uterine fibroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No medical therapy is currently available for the long-term treatment of uterine fibroids.
      The objective of this study is to determine the effects of asoprisnil in uterine fibroid
      growth suppression. Full thickness biopsies obtained from surgical procedures will allow the
      assessment of asoprisnil's effects on the basalis, the myometrium, and on endometrial
      angiogenesis. Various other exploratory immunohistological and biochemical specimens will be
      collected to evaluate the mechanisms of action of asoprisnil in the endometrium, the
      myometrium, and in uterine fibroids.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to the Final Visit in uterine artery blood flow as determined by change in Resistance Index.</measure>
    <time_frame>Final visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in uterine artery blood flow as determined by change in Pulsatility Index.</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphological changes in the endometrium, myometrium and uterine fibroids.</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in menstrual pictogram score.</measure>
    <time_frame>Final Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in volume of the largest fibroid.</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness (post-treatment histologic evaluation).</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in endometrial thickness by transvaginal ultrasound.</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of ovulatory subjects.</measure>
    <time_frame>Final Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Uterine Fibroid Symptom-Quality of Life total symptom severity score and the Uterine Fibroid Symptom-Quality of Life total score.</measure>
    <time_frame>Final Visit</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Uterine Fibroids</condition>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asoprisnil</intervention_name>
    <description>Asoprisnil 10mg Tablet, oral Daily for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>J867</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asoprisnil</intervention_name>
    <description>Asoprisnil 25 mg Tablet, oral Daily for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>J867</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Tablet, oral Daily for 12 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women, at least 18 years of age

          -  Diagnosis of uterine fibroid(s), confirmed by ultrasound

          -  History of menstrual cycles between 17 and 42 days

          -  Otherwise in good health

          -  Scheduled for a hysterectomy at the end of the treatment period

          -  Negative pregnancy test

          -  Agrees to double barrier method of contraception

          -  Pap test with no evidence of malignancy or pre-malignant changes

          -  Endometrial biopsy with no significant histological disorder

        Exclusion Criteria:

          -  Less than 3 months after having a baby or breast-feeding

          -  Any abnormal lab or procedure result the study-doctor considers important

          -  Severe reaction(s) to or are currently using any hormone therapy

          -  History of cancer or alcohol or drug abuse

          -  Diagnosis of Polycystic Ovary Syndrome

          -  History of prolactinoma

          -  Current use of Intrauterine Device

          -  Significant gynecological disorder

          -  Uterine size &gt; 32 weeks gestation

          -  Current diagnosis of endometriosis

          -  Uterine artery embolization within 6 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <results_reference>
    <citation>Williams AR, Critchley HO, Osei J, Ingamells S, Cameron IT, Han C, Chwalisz K. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod. 2007 Jun;22(6):1696-704. Epub 2007 Mar 5.</citation>
    <PMID>17339234</PMID>
  </results_reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>May 27, 2008</last_update_submitted>
  <last_update_submitted_qc>May 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Cynthia Mattia-Goldberg</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Fibroid Uterus</keyword>
  <keyword>Leiomyoma</keyword>
  <keyword>Uterine Fibroids</keyword>
  <keyword>Hysterectomy</keyword>
  <keyword>Asoprisnil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

